India’s Ipca Laboratories has announced its third acquisition in two years with a deal to buy manufacturer Ramdev Chemical Ltd for INR1.1bn ($15.7mn). Ipca said the acquisition would allow the company to “grow its active pharmaceutical ingredient (API) business by adding new molecules in its products basket, with the possibility of forward-integrating such products in its dosage formulations business for the world market.”
Ipca will purchase 100% of shares in Ramdev, which is based in the Palghar district of the western Indian state...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?